Studies for patients with rheumatoid arthritis and for patients with Sjögren's Syndrome (RA)

Studies - Campus Charité Mitte

Trials in rheumatoid arthritis and Sjogren's syndrome are carried out only in Rheumatologie, Campus Charité Mitte.

Biologicals for the treatment of early rheumatoid arthritis (RA)

Various so-called Biologicals are currently approved for the treatment of active rheumatoid arthritis, in case if so-called standard anti-inflammatory drugs are ineffective or poorly tolerated. It is now proven that the early use of those substances, produced with modern biotechnology, is highly effective, increasingly placing those substances in the forefront of research. By administering these biologicals in the early phase of the disease, joint destruction anddeformation, typical for rheumatoid arthritis, may be halted. Associated treatment objectives are to increase the quality of life and to preserve good functional status and ability to work.

 

The Department of Rheumatology at the Campus Charité Mitte conducts several studies for the treatment of the early form of rheumatoid arthritis If you are suspicted of rheumatoid arthritis and you have chronic joint pain and swelling for less than 2 years, then perhaps an opportunity of your participation in one of the above-mentioned Studies may be considered.

 

You may discuss these opportunities to participate in a clinical trial and get further information by dialing  +49 30 450 513 025 (Mr. Zernicke or colleagues).

Biologicals for the treatment of rheumatoid arthritis (RA) associated with ineffectiveness or intolerance of disease-modifying anti-rheumatic drugs (DMARDs)

Biologicals are used to treat rheumatoid arthritis for about 10 years. They affect the immunity in a body by blocking inflammation. By their action, they are biological antagonist of the inflammatory response messengers such as tumor necrosis factor-a and interleukin-6.

 

The Department of Rheumatology at the Campus Charité Mitte conducts several studies with Biologicals for the treatment of rheumatoid arthritis with ineffectiveness or intolerance of disease-modifying anti-rheumatic drugs (DMARDs). These are either already approved substances which are explored for a new indication or novel Biologicals, which are yet to be registered (Phase II to Phase IV). If you are currently taking a disease-modifying anti-rheumatic drug, but the effectiveness is not satisfactory (joint pain and swelling remain), then perhaps an opportunity of your participation in one of the above-mentioned Studies may be considered.

 

You may discuss these opportunities to participate in a clinical trial and get further information by dialing  +49 30 450 513 025 (Mr. Zernicke or colleagues).

Studies for the treatment of primary Sjögren's syndrome

Current treatment strategy of Sjögren's syndrome is targeted to control the sicca symptoms (ineffective production of tear fluid and salivary and nasal secretions) and is mainly symptomatic (targeted on symptoms reduction). In particular, local medications, such as eye drops, are used.

The Department of Rheumatology at the Campus Charité Mitte is currently conducting a study to find out whether the use of a disease-modifying anti-rheumatic drug (so-called DMARD) which is already approved for other rheumatic diseases can improve the symptoms in patients with Sjögren's Syndome. The goal of the study is to investigate the efficacy of this drug based on inflammatory changes in the joints as a part of primary Sjögren's syndrome.

If you are diagnosed with primary Sjögren's syndrome and have joint pain and swelling, then perhaps an opportunity of your participation in the above-mentioned Study may be considered.

You may discuss these opportunities to participate in a clinical trial and get further information by dialing  +49 30 450 513 025 (Mr. Zernicke or colleagues).

Address:

Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie
„Neue Therapien“ Department (Studienabteilung)
Charitéplatz 1 (Hochhaus, 14. Etage)
10117 Berlin

Please note that to be able to participate in the majority of clinical trials, you should be able to speak and read in German.